Profile
Nucleus Capital is a venture capital firm based in Berlin, Germany, founded in 2021. The firm focuses on deep-tech investments, particularly in programmable biology, food technology, and neo-industrials. With a small team of three professionals, Nucleus Capital distinguishes itself by engaging with technical teams at the early stages of their journey, providing support tailored to the unique needs of scientific ventures.
Nucleus Capital invests primarily in Europe and the United States, with a typical check size of up to €1 million. The firm is thesis-driven, concentrating on sectors such as programmable biology, agrifood technology, and green industrials. They focus on pre-seed and seed stages, aiming to be the first believers in frontier founders. Nucleus Capital's portfolio includes companies like Apoha, which develops sensory intelligence technology, and Endolith, which innovates in copper extraction through bioleaching.
Notable investments by Nucleus Capital include Apoha - sensory intelligence technology, Endolith - microbial copper extraction, Triple Bio - animal husbandry solutions, Koppie - beverage innovations, and Telura - alternative energy equipment. These investments reflect the firm's commitment to supporting ventures that address systemic challenges to planetary health.
Industry
Contacts
Instant access on the web. Plans from $129/month — see pricing.